Drug intelligence / Profile preview

Td Vaccine

Development stage: Approved
Lead developer: Panacea Biotec
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Panacea Biotec's Td vaccine is a toxoid-based combination vaccine developed for the prevention of tetanus and diphtheria in adolescents and adults. The vaccine contains purified tetanus toxoid and diphtheria toxoid, which act as antigens to stimulate the immune system to produce protective antitoxin antibodies. This mechanism provides active immunity against the toxins produced by *Clostridium tetani* and *Corynebacterium diphtheriae*. The vaccine has completed Phase II/III clinical trials comparing its safety and immunogenicity to a licensed comparator and is currently in the regulatory filing stage (NDA/BLA filed) in India.

Other names: tetanus and diphtheria vaccineTetanus-diphtheria (Td) vaccine

Targets

TT (Tetanus toxoid)

Beyond the preview

Go deeper on Td Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Td Vaccine.

Explore the full profile